Drug Trial Radar · NCT06704347
Safety Study of XT-150 in Participants With ALS
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Xalud Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
XT-150Biological
XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting adverse events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)Time frame: Up to Day 180
- Number of participants with clinically significant physical examination findingsTime frame: Up to Day 180
- Number of participants with clinically significant vital sign abnormalitiesTime frame: Up to Day 180
- Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to Day 180
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute (St. Joseph's)
Phoenix, Arizona
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford Health
Detroit, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.